JHL Biotech and Affinita Biotech Agree to Partner
News Mar 03, 2016
JHL Biotech, Inc. has announced it has entered into a contract manufacturing master service agreement with Affinita Biotech. The agreement covers a development and manufacturing partnership for Affinita’s oncology monoclonal antibodies.
The agreement, extending to 2020, is estimated to be worth up to US$20 million in value. JHL will
provide cell line development, process development, and manufacturing expertise. The activities will
be carried out in JHL's Zhubei site in Taiwan as well as at JHL’s manufacturing facility in Wuhan,
8th European Clinical Microbiology and Immunology Congress
Jun 12 - Jun 13, 2019